Skip to Main Content

Paper Details

Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.
Leukemia
15
2020
Author NameAffiliation
Christopher A EideKnight Cancer Institute, Oregon Health & Science University
Christopher A EideHoward Hughes Medical Institute
Stephen E KurtzKnight Cancer Institute, Oregon Health & Science University
Andy KaempfKnight Cancer Institute, Oregon Health & Science University
Nicola LongKnight Cancer Institute, Oregon Health & Science University
Anupriya AgarwalKnight Cancer Institute, Oregon Health & Science University
Cristina E TognonKnight Cancer Institute, Oregon Health & Science University
Cristina E TognonHoward Hughes Medical Institute
Motomi MoriKnight Cancer Institute, Oregon Health & Science University
Motomi MoriPortland State University and Oregon Health & Science University School of Public Health
Brian J DrukerKnight Cancer Institute, Oregon Health & Science University
Brian J DrukerHoward Hughes Medical Institute
Bill H ChangKnight Cancer Institute, Oregon Health & Science University
Alexey V DanilovKnight Cancer Institute, Oregon Health & Science University
Jeffrey W TynerKnight Cancer Institute, Oregon Health & Science University
Jeffrey W TynerOregon Health & Science University
  • 1 - 16

Datasets